Sugi Predict
/ Targets
/ PARP2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PARP2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients |
PHASE3 | COMPLETED |
| Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments |
PHASE3 | COMPLETED |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) |
PHASE1/PHASE2 | COMPLETED |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib |
PHASE2 | COMPLETED |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| Trial of Maintenance With Niraparib- Uterine Serous Carcinoma |
PHASE2 | COMPLETED |
| Olaparib In Metastatic Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) |
PHASE1/PHASE2 | RECRUITING |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer |
PHASE1 | COMPLETED |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer |
PHASE1 | UNKNOWN |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors |
PHASE1 | COMPLETED |
| Pre-Operative Radiation and Veliparib for Breast Cancer |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems |
PHASE1 | WITHDRAWN |
| Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer |
PHASE1 | COMPLETED |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts |
PHASE1 | ACTIVE_NOT_RECRUITING |
| AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer |
PHASE1 | COMPLETED |
| PET Imaging of PARP Activity in Cancer |
EARLY_PHASE1 | UNKNOWN |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
nan | NO_LONGER_AVAILABLE |
Related proteins — ESM-2 sequence neighbours (a PARP2 binder may also engage these)